Gradientech receives patent rights in Japan
The diagnostics company Gradientech reports having received a Notice of Allowance in Japan for its QuickMIC® cassette, the single-use test device in the QuickMIC® diagnostic system for ultra-rapid antibiotic susceptibility testing (AST).
Gradientech announces that the Japan Patent Office has recognised the originality of the QuickMIC® cassette construction to be used in automated systems for antibiotic susceptibility testing of microorganisms. The Japanese patent application is based on the International Publication Number WO 2020/204799 and describes the design and functionality of a test device assembly including microfluidic-based sub-parts, an optically transparent mid-part containing the patient’s microorganisms cultured in a stable concentration gradient of antimicrobial stubstances, and a cover part for encapsulation. The Japanese QuickMIC® cassette patent, once registered, is valid until 2040. A granted patent within the same patent family is registered in China.
The test device is part of the CE marked QuickMIC® system by Gradientech, the today fastest automated system on the market for AST-testing of positive blood cultures for improved sepsis patient management.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
Tags:
